QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA approval of Amylyx Pharmaceuticals’ ALS therapy.
View the article
View the article
PROUD SIGNATORIES
We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.